MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI
Old Web
English
Sign In
Email Address
acemap@cs.sjtu.edu.cn
- CCF Conference Analysis
- Map Galaxy
- Academic Report
- What's New
© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.